MA43348A - Conjugués de protéines - Google Patents

Conjugués de protéines

Info

Publication number
MA43348A
MA43348A MA43348A MA43348A MA43348A MA 43348 A MA43348 A MA 43348A MA 43348 A MA43348 A MA 43348A MA 43348 A MA43348 A MA 43348A MA 43348 A MA43348 A MA 43348A
Authority
MA
Morocco
Prior art keywords
protein conjugates
conjugates
proteins
polypeptides
compounds include
Prior art date
Application number
MA43348A
Other languages
English (en)
Inventor
Emiliano Cló
Mikael Kofod-Hansen
Nils Langeland Ohansen
Henrik Sune Ramírez-Andersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54252136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43348(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of MA43348A publication Critical patent/MA43348A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des conjugués de protéines et en particulier des conjugués de plus de deux protéines ou polypeptides. Les composés comprennent un fragment de liaison trivalent qui permet une production efficace de produits souhaités.
MA43348A 2015-10-01 Conjugués de protéines MA43348A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15187937 2015-10-01

Publications (1)

Publication Number Publication Date
MA43348A true MA43348A (fr) 2018-08-08

Family

ID=54252136

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43348A MA43348A (fr) 2015-10-01 Conjugués de protéines

Country Status (7)

Country Link
US (1) US11292825B2 (fr)
EP (1) EP3355931B1 (fr)
JP (1) JP6949832B2 (fr)
CN (1) CN108136043B (fr)
ES (1) ES2985999T3 (fr)
MA (1) MA43348A (fr)
WO (1) WO2017055582A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3303380B1 (fr) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulines à extensions recombinées polaires
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
PL3532497T3 (pl) 2016-10-26 2024-11-04 The Board Of Trustees Of The Leland Stanford Junior University Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji
US10864279B2 (en) * 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
JP2020513019A (ja) * 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
EP4464719A3 (fr) * 2017-08-04 2025-03-05 Amgen Inc. Procédé de conjugaison de cys-mabs
EP4241789A4 (fr) * 2020-12-08 2025-04-02 Nona Biosciences (Shanghai) Co., Ltd. Conjugué protéine-médicament et procédé de conjugaison spécifique à un site
CN113024669B (zh) * 2021-03-12 2022-06-14 北京华科泰生物技术股份有限公司 含氨基或羧基基团物质标记的rbp抗体、人rbp免疫层析检测试剂盒及其制备方法
CN115819611B (zh) * 2021-12-30 2024-05-28 君合盟生物制药(杭州)有限公司 生长激素融合蛋白及其制备方法和用途
CN115845032A (zh) * 2022-10-28 2023-03-28 深圳科兴药业有限公司 生长激素fc融合蛋白注射液及其用途
WO2025184552A2 (fr) * 2024-03-01 2025-09-04 The Scripps Research Institute Conjugués peptidiques doubles gip/glp-1 et procédés d'utilisation

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE257197C (fr)
DE286509C (fr)
US3914252A (en) 1971-03-15 1975-10-21 Continental Oil Co Preparation of N-iodocompounds
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
CA2658039A1 (fr) 1995-09-21 1997-03-27 Genentech, Inc. Variants de l'hormone de croissance humaine
WO1998022577A1 (fr) 1996-11-15 1998-05-28 Maria Grazia Masucci Proteines de fusion a demi-vie allongee
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
ES2317843T3 (es) 1999-07-13 2009-05-01 Bolder Biotechnology, Inc. Proteinas de fusion de eritropoyetina-inmunoglobulina.
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
DE60041564D1 (de) 1999-12-24 2009-03-26 Genentech Inc Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
AU2002219021A1 (en) 2001-01-11 2002-07-24 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
US20020169125A1 (en) 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
WO2003042245A2 (fr) 2001-11-12 2003-05-22 University Of Wales College Of Medicine Variations de l'hormone de croissance chez les humains et leurs utilisations
GB2389115B (en) 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
EP3321282A1 (fr) 2002-09-27 2018-05-16 Xencor, Inc. Variantes fc optimisées et leurs procédés de génération
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2438098T3 (es) 2003-11-13 2014-01-15 Hanmi Science Co., Ltd. Composición farmacéutica que comprende un Fc de inmunoglobulina como vehículo
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
KR100594607B1 (ko) 2004-11-03 2006-06-30 재단법인서울대학교산학협력재단 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
MX2007008982A (es) 2005-01-25 2007-12-06 Cell Therapeutics Inc Conjugados de proteinas biologicamente activas que tienen una vida media modificada in vivo.
US20090036353A1 (en) 2005-01-27 2009-02-05 Novo Nordisk A/S Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers
BRPI0607775A2 (pt) 2005-02-16 2018-06-26 Novo Nordisk As conjugado, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de doença
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
EP1996220B2 (fr) 2006-03-06 2023-08-16 Amunix Operating Inc. Polymères recombinés non structurés et utilisations correspondantes
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US8492129B2 (en) 2005-12-12 2013-07-23 Innova Biosciences, Ltd. Production of conjugates
ES2779992T3 (es) 2005-12-20 2020-08-21 Univ Duke Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
EP2054437A2 (fr) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Protéines de fusion d'albumine et d'insuline
PT2094728E (pt) 2006-10-26 2013-05-27 Janssen Biotech Inc Métodos de adaptação de anticorpos monoclonais ao ser humano
WO2008049711A1 (fr) 2006-10-27 2008-05-02 Novo Nordisk A/S Insuline à peptide ajouté
WO2008147456A2 (fr) 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Systèmes d'administration de médicaments en utilisant des fragments fc
WO2008092117A2 (fr) 2007-01-25 2008-07-31 Xencor, Inc. Nouvelles insertions, délétions et substitutions d'immunoglobulines
KR20080095141A (ko) 2007-04-23 2008-10-28 포항공과대학교 산학협력단 인간 알부민 링커를 통하여 면역글로불린의 Ｆｃ에 결합된생리학적 활성 폴리펩티드의 융합 폴리펩티드, 및 이의제조방법
ES2415604T3 (es) 2007-05-30 2013-07-26 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
CA2688275A1 (fr) 2007-05-31 2008-12-04 Genmab A/S Anticorps igg4 stables
WO2009015345A1 (fr) 2007-07-25 2009-01-29 Amgen Inc. Compositions pharmaceutiques comprenant des protéines de fusion fc
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
JP5703020B2 (ja) 2007-08-24 2015-04-15 ノボ ノルディスク ヘルス ケア アーゲー タンパク質を選択的に修飾するための組成物と方法
JP5314033B2 (ja) 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
KR20170116193A (ko) 2008-06-20 2017-10-18 노파르티스 아게 응집이 감소된 면역글로불린
WO2010001196A1 (fr) 2008-07-02 2010-01-07 Koninklijke Philips Electronics N.V. Configuration de ressort en v et ensembles de fixation d'extrémité pour celle-ci destinés à être utilisés dans un appareil de soins d'hygiène corporelle
KR101200659B1 (ko) 2008-07-23 2012-11-12 한미사이언스 주식회사 세 말단 반응기를 갖는 비펩타이드성 중합체를 이용한 생리활성 폴리펩타이드 약물 결합체
EP2356142B1 (fr) 2008-11-10 2016-08-10 Novo Nordisk A/S Souche de e. coli bl21 sans cluster fonctionnel de gènes de la capsule du group ii.
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
CA2774552A1 (fr) 2009-09-30 2011-04-07 Glaxo Group Limited Fusions de medicaments et conjugues presentant une demi-vie prolongee
BR112012010252A2 (pt) 2009-10-29 2016-12-06 Janssen Biotech Inc variantes de glicosilação de anticorpo
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
CN118767115A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
SI2571510T1 (sl) 2010-05-21 2019-02-28 Xl-Protein Gmbh Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
WO2012010516A1 (fr) 2010-07-22 2012-01-26 Novo Nordisk Health Care Ag Conjugués d'hormone de croissance
US9783571B2 (en) * 2011-04-05 2017-10-10 Warham Lance Martin Isolation of cysteine containing peptides
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CA3179537A1 (fr) * 2012-02-27 2013-09-06 Amunix Pharmaceuticals, Inc. Compositions de conjugues xten et leurs procedes de preparation
JP6290187B2 (ja) 2012-05-11 2018-03-07 クランツ，アレクサンダー 癌の処置のためのタンパク質の部位特異的標識及び標的送達
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
US20160115216A1 (en) 2013-06-07 2016-04-28 Novo Nordisk A/S Method for Making Mature Insulin Polypeptides
ES2927607T3 (es) 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
CN105764530B (zh) 2013-11-26 2019-09-13 诺华股份有限公司 用于对酮修饰的多肽类进行肟缀合的方法
JP6620094B2 (ja) 2013-11-26 2019-12-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答を調節するための組成物および方法
TW201619188A (zh) 2014-03-05 2016-06-01 優稀美生物醫藥公司 多聚體Ｆｃ蛋白質
ES2905085T3 (es) 2014-09-17 2022-04-07 Novo Nordisk As Anticuerpos que pueden unirse a dos epítopos en el inhibidor de la vía del factor tisular (1-161)
JP2018508504A (ja) 2015-02-17 2018-03-29 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリンまたはインスリンアナログ結合体
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
EP3303380B1 (fr) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulines à extensions recombinées polaires
PL3334462T3 (pl) 2015-08-14 2022-05-09 RemeGen Biosciences, Inc. Kowalencyjne linkery w koniugatach przeciwciało-lek oraz sposoby ich wytwarzania i zastosowania
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
CN112839681A (zh) 2018-10-10 2021-05-25 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物及其医学用途

Also Published As

Publication number Publication date
ES2985999T3 (es) 2024-11-08
US11292825B2 (en) 2022-04-05
EP3355931A1 (fr) 2018-08-08
JP2018535195A (ja) 2018-11-29
EP3355931C0 (fr) 2024-06-26
WO2017055582A1 (fr) 2017-04-06
US20180282387A1 (en) 2018-10-04
CN108136043B (zh) 2022-09-06
JP6949832B2 (ja) 2021-10-13
EP3355931B1 (fr) 2024-06-26
CN108136043A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
IL272064A (en) Binding proteins 1
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
PH12017502180A1 (en) Tau-binding antibodies
PH12018500657A1 (en) Optimized variants of anti-vegf antibodies
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
MA50942A (fr) Protéines de liaison à l'adn modifiées
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471B1 (fr) Compositions comprenant des souches bactériennes
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
PH12017502207B1 (en) Tau-binding antibodies
MX2016011641A (es) Procedimiento de preparacion de proteinas plasmaticas humanas.
MX2017001038A (es) Variantes de proteina de unión al factor h y metodos de uso de estas.
NZ747665A (en) Cd200 mutant and its uses
MA43348A (fr) Conjugués de protéines
GB201917046D0 (en) Improved protein production
SG11202006140TA (en) Process for providing pegylated protein composition
GB201919294D0 (en) Antibodies or binding proteins
PT3806660T (pt) Barra proteica
EP3309169A4 (fr) Anticorps se liant spécifiquement à des peptides dérivés de la vimentine isolés ou fragment de liaison du peptide
PH12017502277A1 (en) Multi-specific binding proteins
FR3016888B1 (fr) Synthetases de la colistine et cluster de genes correspondants
SG11202005990RA (en) Process for providing pegylated protein composition